<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01500850</url>
  </required_header>
  <id_info>
    <org_study_id>Lantu_L_05720</org_study_id>
    <nct_id>NCT01500850</nct_id>
  </id_info>
  <brief_title>Establishing Cardiovascular Biomarkers to Define Preferred Lantus® Use</brief_title>
  <official_title>Establishing Cardiovascular Biomarkers to Define Preferred Lantus® Use.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ikfe-CRO GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>IKFE Institute for Clinical Research and Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>ikfe-CRO GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to observe changes in cardiovascular biomarkers during treatment
      with Lantus in patients with Type 2 Diabetes mellitus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Phase IV

        -  Indication: Diabetes mellitus Type 2

        -  Primary objective:

      To compare fasting intact proinsulin secretion at the beginning and after a 24 week treatment
      period.

      - Secondary objectives: To evaluate changes in the parameters

        -  insulin,

        -  glucose,

        -  intact proinsulin (after a glucose challenge),

        -  hsCRP,

        -  adiponectin,

        -  MMP-9,

        -  HbA1c,

        -  weight

      after 24 weeks of treatment.

      To investigate the changes of

        -  glucose,

        -  intact proinsulin,

        -  hsCRP,

        -  adiponectin,

        -  HbA1c

        -  weight

      between visit 2 (baseline), visit 6 (12 weeks) and visit 8 (final visit after 24 weeks).

      To investigate the number of patients with normal values for parameters hsCRP, adiponectin,
      and intact proinsulin after 24 weeks of treatment (responder rates).

      -Primary efficacy variable: Fasting intact proinsulin concentration at timepoint Visit 2
      (Baseline) and Visit 8 (after 24 week treatment)

      -Secondary efficacy variables: All secondary parameters will be assessed after 24 weeks of
      treatment and compared versus baseline assessment.

        -  Weight

        -  hsCRP

        -  Adiponectin

        -  MMP-9

        -  OGTT parameters (insulin, intact proinsulin, glucose at time point 0, 60 and 120 minutes
           after 24 weeks

        -  HOMA-IR score

        -  HbA1c

      Additionally the following parameters will be assessed at visit 6 and will be compared with
      visit 2 and visit 8:

        -  Weight

        -  hsCRP

        -  Adiponectin

        -  Fasting intact Proinsulin

        -  Glucose

        -  HbA1c

        -  Safety Variables:

        -  Adverse Events

        -  Hypoglycaemic events

      Medication/Dosage:

      Insulin glargine, dose individually adapted to reach treatment goal (FBG ≤ 100 mg/dL)NPH
      Insulin, dose individually adapted to reach treatment goal (FBG ≤ 100 mg/dL)Insulin
      glulisine, dose individually adapted to reach treatment goal (FBG ≤ 100 mg/dL)Human Insulin,
      dose individually adapted to reach treatment goal (FBG ≤ 100 mg/dL)

      -Study Duration: Duration of study participation for one patient is approximately 26 weeks.
      Overall total duration of the study is approximately 10 months.

      Design:

      This is a randomized in four arms, open-label, multi-center study. Population Patients with
      Type 2 Diabetes mellitus, Sample Size n = 60 (15 per arm)
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2011</start_date>
  <completion_date type="Anticipated">October 2012</completion_date>
  <primary_completion_date type="Anticipated">October 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fasting Intact Proinsulin</measure>
    <time_frame>Change from baseline at 24 weeks</time_frame>
    <description>The difference of fasting intact proinsulin after 24 weeks of treatment compared to baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Weight</measure>
    <time_frame>Baseline and after 24 weeks of treatment.</time_frame>
    <description>To evaluate the changes of weight after 24 weeks of treatment compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hsCRP</measure>
    <time_frame>Baseline and after 24 weeks of treatment.</time_frame>
    <description>To evaluate changes of hsCRP after 24 weeks of treatment compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adiponectin</measure>
    <time_frame>Baseline and after 24 weeks of treatment.</time_frame>
    <description>To evaluate changes of adiponectin after 24 weeks of treatment compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MMP-9</measure>
    <time_frame>Baseline and after 24 weeks of treatment.</time_frame>
    <description>To evaluate changes of MMP-9 after 24 weeks of treatment compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OGTT parameters (insulin, intact proinsulin, glucose at time point 0, 60 and 120 minutes after 24 weeks</measure>
    <time_frame>Baseline and after 24 weeks of treatment.</time_frame>
    <description>To evaluate changes of OGTT parameters (insulin, intact proinsulin, glucose at time point 0, 60 and 120 minutes) after 24 weeks of treatment compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HOMA-IR score</measure>
    <time_frame>Baseline and after 24 weeks of treatment.</time_frame>
    <description>To evaluate changes of HOMA-IR score after 24 weeks of treatment compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c</measure>
    <time_frame>Baseline and after 24 weeks of treatment.</time_frame>
    <description>To evaluate changes of HbA1C after 24 weeks of treatment compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight</measure>
    <time_frame>After 12 weeks of treatment compared to baseline and to 24 weeks of treatment.</time_frame>
    <description>To evaluate changes of weight after 12 weeks of treatment compared to baseline and compared to 24 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hsCRP</measure>
    <time_frame>After 12 weeks of treatment compared to baseline and to 24 weeks of treatment.</time_frame>
    <description>To evaluate changes of hsCRP after 12 weeks of treatment compared to baseline and compared to 24 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adiponectin</measure>
    <time_frame>After 12 weeks of treatment compared to baseline and to 24 weeks of treatment.</time_frame>
    <description>To evaluate changes of adiponectin after 12 weeks of treatment compared to baseline and compared to 24 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting intact Proinsulin</measure>
    <time_frame>After 12 weeks of treatment compared to baseline and to 24 weeks of treatment.</time_frame>
    <description>To evaluate changes of fasting intact proinsulin after 12 weeks of treatment compared to baseline and compared to 24 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose</measure>
    <time_frame>After 12 weeks of treatment compared to baseline and to 24 weeks of treatment.</time_frame>
    <description>To evaluate changes of Glucose after 12 weeks of treatment compared to baseline and compared to 24 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c</measure>
    <time_frame>After 12 weeks of treatment compared to baseline and to 24 weeks of treatment.</time_frame>
    <description>To evaluate changes of HbA1c after 12 weeks of treatment compared to baseline and compared to 24 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responder rate</measure>
    <time_frame>After 24 weeks of treatment compared to baseline.</time_frame>
    <description>To investigate the number of patients with normal values for parameters hsCRP, adiponectin, and intact proinsulin after 24 weeks of treatment (responder rates).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemic events.</measure>
    <time_frame>Baseline up to 24 weeks.</time_frame>
    <description>Hypoglycemic events defined as blood glucose below 63 mg/dl.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Insulin-requiring Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>NPH insulin + insulin glulisine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be randomized to be treated with NPH insulin + Insulin Glulisine for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NPH insulin + human insulin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be randomized to be treated with NPH insulin + human insulin for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin glargine + insulin glulisine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be randomized to be treated with insulin glargine + insulin glulisine for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin Glargine + Human insulin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be randomized to be treated with insulin glargine + human insulin for 24 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nph insulin</intervention_name>
    <description>Dosage will be pro re nata. Patients should aim an blood glucose level of ≤ 100 mg/dL.</description>
    <arm_group_label>NPH insulin + insulin glulisine</arm_group_label>
    <other_name>Insuman Basal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>human insulin</intervention_name>
    <description>Dosage will be pro re nata. Patients should aim an blood glucose level of ≤ 100 mg/dL.
human insulin: bolus injections before each main meal</description>
    <arm_group_label>NPH insulin + human insulin</arm_group_label>
    <arm_group_label>Insulin Glargine + Human insulin</arm_group_label>
    <other_name>Insuman Rapid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Glargine</intervention_name>
    <description>Dosage will be pro re nata. Patients should aim an blood glucose level of ≤ 100 mg/dL.</description>
    <arm_group_label>Insulin glargine + insulin glulisine</arm_group_label>
    <arm_group_label>Insulin Glargine + Human insulin</arm_group_label>
    <other_name>Lantus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin glulisine</intervention_name>
    <description>Dosage will be pro re nata. Patients should aim an blood glucose level of ≤ 100 mg/dL.
Insulin glulisine: bolus injections before each main meal</description>
    <arm_group_label>NPH insulin + insulin glulisine</arm_group_label>
    <arm_group_label>Insulin glargine + insulin glulisine</arm_group_label>
    <other_name>Apidra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Give written informed consent.

          -  Patient consents that his/her family physician/diabetologist will be informed of trial
             participation

          -  Type-2 diabetes mellitus ≥ 1 year of diagnosis (male and female)

          -  Experienced in self blood glucose measurement for ≥ 3 months.

          -  HbA1c ≤ 9% and &gt;6,5%

          -  BMI &gt; 30 kg/m²

          -  Age ≥ 18 years

          -  Waist circumference &gt; 88 cm (female) and &gt; 102 cm (male)

          -  NPH insulin treatment plus 1 or 2 OAD (except TZD)

        Exclusion Criteria:

          -  History of drug or alcohol abuse within the last five years prior to screening

          -  Anamnestic history of hypersensitivity to the study drugs (or any component of the
             study drug) or to drugs with similar chemical structures

          -  History of severe or multiple allergies

          -  Treatment with any other investigational drug within 3 months prior to screening

          -  Progressive fatal disease

          -  History of significant cardiovascular, respiratory, gastrointestinal, hepatic (ALAT
             and/or ASAT &gt; 3 times the normal reference range), renal (creatinine &gt; 1.3 mg/dl in
             women and &gt;1.6 mg/dl in men), neurological, psychiatric and/or hematological disease
             as judged by the investigator

          -  Pregnant or lactating women

          -  Sexually active women of childbearing potential not consistently and correctly
             practicing birth control by implants, injectables, combined oral contraceptives,
             hormonal intrauterine devices (IUDs), sexual abstinence or vasectomized partner

          -  Treatment with GLP1-analog or Thiazolidinediones (TZD)

          -  hsCRP &gt; 10 mg/l (by rapid test at screening visit).

          -  Lack of compliance or other similar reason that, according to investigator, precludes
             satisfactory participation in the study

          -  Type 1 Diabetes mellitus

          -  Patients already treated with intensified conventional insulin therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Pfützner, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ikfe GmbH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andreas Pfützner, Professor</last_name>
    <phone>00496131-57636-0</phone>
    <phone_ext>20</phone_ext>
    <email>andreasp@ikfe.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Thomas Forst, Professor</last_name>
    <phone>00496131-57636-0</phone>
    <phone_ext>16</phone_ext>
    <email>thomasf@ikfe.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>ikfe GmbH</name>
      <address>
        <city>Mainz</city>
        <state>Rheinland-Pfalz</state>
        <zip>55116</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Forst, MD</last_name>
      <phone>+49(0) 6131-576 36 -40</phone>
      <phone_ext>16</phone_ext>
      <email>thomasf@ikfe.de</email>
    </contact>
    <contact_backup>
      <last_name>Daniela Sachsenheimer, MD</last_name>
      <phone>+49(0) 6131-576 36 40</phone>
      <phone_ext>46</phone_ext>
      <email>danielas@ikfe.de</email>
    </contact_backup>
    <investigator>
      <last_name>Daniela Sachsenheimer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephanie Helleberg, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephan Diessel</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2011</study_first_submitted>
  <study_first_submitted_qc>December 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 29, 2011</study_first_posted>
  <last_update_submitted>December 23, 2011</last_update_submitted>
  <last_update_submitted_qc>December 23, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 29, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 Diabetes mellitus</keyword>
  <keyword>NPH insulin</keyword>
  <keyword>Insulin Glargine</keyword>
  <keyword>cardiovascular biomarkers</keyword>
  <keyword>hsCRP, adiponectin</keyword>
  <keyword>intact proinsulin</keyword>
  <keyword>cardiovascular risk</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin glulisine</mesh_term>
    <mesh_term>Isophane insulin, beef</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
    <mesh_term>Insulin, Isophane</mesh_term>
    <mesh_term>Isophane Insulin, Human</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

